Synageva posts positive top-line data for enzyme replacement therapy
By Michael Fitzhugh
Tuesday, July 1, 2014
Rare disease specialist Synageva Biopharma Corp. reported top-line phase III data showing that sebelipase alfa, its enzyme replacement therapy for LAL deficiency, met its primary endpoint and several secondary endpoints.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.